I did write
a post a while back highlighting an excellent on line resource that gives
clinicians data on 81 treatable forms of Intellectual Disability, ID (formerly
known as mental retardation, MR).
There is a
big overlap between the causes of some ID and causes of some autism.
If you have
a case of autism, it is worth reviewing the 81 treatable forms of ID, just in
case you have one, even a mild version causing minimal ID. Partial dysfunctions certainly are possible, as we saw with biotin.
It is also
very interesting to look through the therapies used and see how they overlap
with those used by people in their n=1 case of autism.
For example the therapy for SLOS (Smith–Lemli–Opitz
syndrome) which is related to very low cholesterol is to give cholesterol and
Simvastatin. Simvastatin is widely used
in older people to LOWER cholesterol. Statins have several other known modes of action. We use Atorvastatin.
Note all the vitamin related syndromes etc.
The data is
all on the online resource that is highlighted at the top of every page in this
blog, but as one regular reader from Hong Kong pointed out, it is better to actually read it in
table form.
He recommended the two
papers below. I reproduced some of the
tables, but I suggest you click the link to read the papers.
The formatting is not so good, since I have cut and paste from the papers.
You have the syndromes, their therapies and their diagnostic tests.
Complicated questions should be addressed to the authors of the papers or your doctor.
Table 2Overview of all 81
treatable IDs.In this table, the IEMs are grouped according to the
biochemical phenotype as presented in standard textbooks, and alphabetically.
Of note, primary CoQ deficiency was considered as one single IEM even though
more though 6 genes have been described; this is true as well for MELAS and
Pyruvate Dehydrogenase Complex deficiency.
|
||||
Biochemical category
|
Disease name
|
OMIM#
|
Biochemical deficiency
|
Gene(s)
|
Amino acids
|
HHH syndrome (hyperornithinemia, hyperammonemia,
homocitrullinemia)
|
238970
|
Ornithine translocase
|
SLC25A15 (AR)
|
l.o. Non-ketotic hyperglycinemia
|
605899
|
Aminomethyltransferase/glycine decarboxylase/glycine cleavage
system H protein
|
AMT/GLDC/GCSH (AR)
|
|
Phenylketonuria
|
261600
|
Phenylalanine hydroxylase
|
PAH (AR)
|
|
PHGDH deficiency(Serine deficiency)
|
601815
|
Phosphoglycerate dehydrogenase
|
PHGDH (AR)
|
|
PSAT deficiency(Serine deficiency)
|
610992
|
Phosphoserine aminotransferase
|
PSAT1 (AR)
|
|
PSPH deficiency(Serine deficiency)
|
614023
|
Phosphoserine phosphatase
|
PSPH (AR)
|
|
Tyrosinemia type II
|
276600
|
Cytosolic tyrosine aminotransferase
|
TAT (AR)
|
|
Cholesterol & bile acids
|
Cerebrotendinous xanthomatosis
|
213700
|
Sterol-27-hydroxylase
|
CYP27A1 (AR)
|
Smith–Lemli–Opitz Syndrome
|
270400
|
7-Dehydroxycholesterol reductase
|
DHCR7 (AR)
|
|
Creatine
|
AGAT deficiency
|
612718
|
Arginine: glycine amidinotransferase
|
GATM (AR)
|
Creatine transporter Defect
|
300352
|
Creatine transporter
|
SLC6A8 (X-linked)
|
|
GAMT deficiency
|
612736
|
Guanidino-acetate-N-methyltransferase
|
GAMT (AR)
|
|
Fatty aldehydes
|
Sjögren–Larsson syndrome
|
270200
|
Fatty aldehyde dehydrogenase
|
ALDH3A2 (AR)
|
Glucose transport & regulation
|
GLUT1 deficiency syndrome
|
606777
|
Glucose transporter blood–brain barrier
|
SLC2A1 (AR)
|
Hyperinsulinism hyperammonemia syndrome
|
606762
|
Glutamate dehydrogenase superactivity
|
GLUD1 (AR)
|
|
Hyperhomocysteinemia
|
Cobalamin C deficiency
|
277400
|
Methylmalonyl-CoA mutase and homocysteine :
methyltetrahydrofolate methyltransferase
|
MMACHC (AR)
|
Cobalamin D deficiency
|
277410
|
C2ORF25 protein
|
MMADHC (AR)
|
|
Cobalamin E deficiency
|
236270
|
Methionine synthase reductase
|
MTRR (AR)
|
|
Cobalamin F deficiency
|
277380
|
Lysosomal cobalamin exporter
|
LMBRD1 (AR)
|
|
Cobalamin G deficiency
|
250940
|
5-Methyltetrahydrofolate-homocysteine S-methyltransferase
|
MTR (AR)
|
|
Homocystinuria
|
236200
|
Cystathatione β-synthase
|
CBS (AR)
|
|
l.o. MTHFR deficiency
|
236250
|
Methylenetetrahydrofolate reductase deficiency
|
MTHFR (AR)
|
|
Lysosomes
|
α-Mannosidosis
|
248500
|
α-Mannosidase
|
MAN2B1 (AR)
|
Aspartylglucosaminuria
|
208400
|
Aspartylglucosaminidase
|
AGA (AR)
|
|
Gaucher disease type III
|
231000
|
ß-Glucosidase
|
GBA (AR)
|
|
Hunter syndrome (MPS II)
|
309900
|
Iduronate-2-sulfatase
|
IDS (X-linked)
|
|
Hurler syndrome (MPS I)
|
607014
|
α-L-iduronidase
|
IDUA (AR)
|
|
l.o. Metachromatic leukodystrophy
|
250100
|
Arylsulfatase A
|
ARSA (AR)
|
|
Niemann–Pick disease type C
|
257220
|
Intracellular transport cholesterol & sphingosines
|
NPC1 NPC2 (AR)
|
|
Sanfilippo syndrome A (MPS IIIa)
|
252900
|
Heparan-N-sulfatase
|
SGSH (AR)
|
|
Sanfilippo syndrome B (MPS IIIb)
|
252920
|
N-acetyl-glucosaminidase
|
NAGLU (AR)
|
|
Sanfilippo syndrome C (MPS IIIc)
|
252930
|
Acetyl-CoA glucosamine-N-acetyl transferase
|
HGSNAT (AR)
|
|
Sanfilippo syndrome D (MPS IIId)
|
252940
|
N-acetyl-glucosamine-6-Sulfatase
|
GNS (AR)
|
|
Sly syndrome (MPS VII)
|
253220
|
β-glucuronidase
|
GUSB (AR)
|
|
Metals
|
Aceruloplasminemia
|
604290
|
Ceruloplasmin (iron homeostasis)
|
CP (AR)
|
Menkes disease/Occipital horn syndrome
|
304150
|
Copper transport protein (efflux from cell)
|
ATP7A (AR)
|
|
Wilson disease
|
277900
|
Copper transport protein (liver to bile)
|
ATP7B (AR)
|
|
Mitochondria
|
Co enzyme Q10 deficiency
|
607426
|
Coenzyme Q2 or mitochondrial
parahydroxybenzoate-polyprenyltransferase; aprataxin; prenyl diphosphate
synthase subunit 1; prenyl diphosphate synthase subunit 2; coenzyme Q8;
coenzyme Q9
|
COQ2, APTX, PDSS1, PDSS2, CABC1, COQ9 (most AR)
|
MELAS
|
540000
|
Mitochondrial energy deficiency
|
MTTL1, MTTQ,MTTH, MTTK,MTTC, MTTS1,MTND1, MTND5,MTND6, MTTS2
(Mt)
|
|
PDH complex deficiency
|
OMIM# according to each enzyme subunit deficiency: 312170;
245348; 245349
|
Pyruvate dehydrogenase complex (E1α, E2, E3)
|
PDHA1 (X-linked), DLAT (AR), PDHX (AR)
|
|
Neurotransmission
|
DHPR deficiency (biopterin deficiency)
|
261630
|
Dihydropteridine reductase
|
QDPR (AR)
|
GTPCH1 deficiency (biopterin deficiency)
|
233910
|
GTP cyclohydrolase
|
GCH1 (AR)
|
|
PCD deficiency (biopterin deficiency)
|
264070
|
Pterin-4α-carbinolamine dehydratase
|
PCBD1 (AR)
|
|
PTPS deficiency (biopterin deficiency)
|
261640
|
6-Pyruvoyltetrahydropterin synthase
|
PTS (AR)
|
|
SPR deficiency (biopterin deficiency)
|
612716
|
Sepiapterin reductase
|
SPR (AR)
|
|
SSADH deficiency
|
271980
|
Succinic semialdehyde dehydrogenase
|
ALDH5A1 (AR)
|
|
Tyrosine Hydroxylase Deficiency
|
605407
|
Tyrosine Hydroxylase
|
TH (AR)
|
|
Organic acids
|
3-Methylcrotonyl glycinuria
|
GENE OMIM # 210200; 210210
|
3-Methylcrotonyl CoA carboxylase (3-MCC)
|
MCC1/MCC2 (AR)
|
3-Methylglutaconic aciduria type I
|
250950
|
3-Methylglutaconyl-CoA hydratase
|
AUH (AR)
|
|
β-Ketothiolase deficiency
|
203750
|
Mitochondrial acetoacetyl-CoA thiolase
|
ACAT1 (AR)
|
|
Cobalamin A deficiency
|
251100
|
MMAA protein
|
MMAA (AR)
|
|
Cobalamin B deficiency
|
251110
|
Cob(I)alamin adenosyltransferase
|
MMAB (AR)
|
|
Ethylmalonic encephalopathy
|
602473
|
Mitochondrial sulfur dioxygenase
|
ETHE1 (AR)
|
|
l.o. Glutaric acidemia I
|
231670
|
Glutaryl-CoA dehydrogenase
|
GCDH (AR)
|
|
Glutaric acidemia II
|
231680
|
Multiple acyl-CoA dehydrogenase
|
ETFA, ETFB,ETFDH (AR)
|
|
HMG-CoA lyase deficiency
|
246450
|
3-Hydroxy-3-methylglutaryl-CoA lyase
|
HMGCL (AR)
|
|
l.o. Isovaleric acidemia
|
243500
|
Isovaleryl-CoA dehydrogenase
|
IVD (AR)
|
|
Maple syrup urine disease (variant)
|
248600
|
Branched-chain 2-ketoacid complex
|
BCKDHA/BCKDHB/ DBT (AR)
|
|
l.o. Methylmalonic acidemia
|
251000
|
Methylmalonyl-CoA mutase
|
MUT (AR)
|
|
MHBD deficiency
|
300438
|
2-Methyl-3-hydroxybutyryl-CoA dehydrogenase
|
HSD17B10 (X-linked recessive)
|
|
mHMG-CoA synthase deficiency
|
605911
|
Mitochondrial 3-hydroxy-3-Methylglutaryl-CoA synthase
|
HMGCS2 (AR)
|
|
l.o. Propionic acidemia
|
606054
|
Propionyl-CoA carboxylase
|
PCCA/PCCB (AR)
|
|
SCOT deficiency
|
245050
|
Succinyl-CoA 3-oxoacid CoA transferase
|
OXCT1 (AR)
|
|
Peroxisomes
|
X-linked adrenoleukodystrophy
|
300100
|
Peroxisomal transport membrane protein ALDP
|
ABCD1 (X-linked)
|
Pyrimidines
|
Pyrimidine 5-nucleotidase superactivity
|
GENE OMIM # 606224
|
Pyrimidine-5-nucleotidase Superactivity
|
NT5C3 (AR)
|
Urea cycle
|
l.o. Argininemia
|
207800
|
Arginase
|
ARG1 (AR)
|
l.o. Argininosuccinic aciduria
|
207900
|
Argininosuccinate lyase
|
ASL (AR)
|
|
l.o. Citrullinemia
|
215700
|
Argininosuccinate Synthetase
|
ASS1 (AR)
|
|
Citrullinemia type II
|
605814
|
Citrin (aspartate–glutamate carrier)
|
SLC25A13
|
|
l.o. CPS deficiency
|
237300
|
Carbamoyl phosphate synthetase
|
CPS1 (AR)
|
|
l.o. NAGS deficiency
|
237310
|
N-acetylglutamate synthetase
|
NAGS (AR)
|
|
l.o. OTC Deficiency
|
311250
|
Ornithine transcarbamoylase
|
OTC (X-linked)
|
|
Vitamins/co-factors
|
Biotinidase deficiency
|
253260
|
Biotinidase
|
BTD (AR)
|
Biotin responsive basal ganglia disease
|
607483
|
Biotin transport
|
SLC19A3(AR)
|
|
Cerebral folate receptor-α deficiency
|
613068
|
a.o. Cerebral folate transporter
|
FOLR1 (AR)
|
|
Congenital intrinsic factor deficiency
|
261000
|
Intrinsic factor deficiency
|
GIF (AR)
|
|
Holocarboxylase synthetase deficiency
|
253270
|
Holocarboxylase synthetase
|
HLCS (AR)
|
|
Imerslund Gräsbeck syndrome
|
261100
|
IF-Cbl receptor defects (cubulin/amnionless)
|
CUBN & AMN (AR)
|
|
Molybdenum co-factor deficiency type A
|
252150
|
Sulfite oxidase & xanthine dehydrogenase & aldehyde
oxidase
|
MOCS1, MOCS2,(AR)
|
|
Pyridoxine dependent epilepsy
|
266100
|
Pyridoxine phosphate oxidase
|
ALDH7A1 (AR),
|
|
Thiamine responsive encephalopathy
|
606152
|
Thiamine transport
|
SLC19A3 (AR)
|
Table 5Overview of all causal therapies (n=91).This Table provides an
overview of the specific therapy/-ies available for each IEM with relevant
level(s) of evidence, therapeutic effect(s) on primary and/or secondary
outcomes and use in clinical practice. For 10 IEMs, two therapies are
available; these are listed separately (in brackets).
|
|||||
Disease name
|
Therapeutic modality (−ies)
|
Level of evidence
|
Clinical practice
|
Treatment effect
|
Literature references
|
Aceruloplasminemia
|
Iron chelation
|
4
|
Standard of care
|
D,E
|
|
(X-linked)adrenoleukodystrophy
|
Stemcell transplantation (Gene
therapy)
|
1c (5)
|
Individual basis (Individual basis)
|
D,E (D,E)
|
|
AGAT deficiency
|
Creatine supplements
|
4
|
Standard of care
|
A,D
|
|
α-Mannosidosis
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
[54
|
l.o. Argininemia
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
l.o. Argininosuccinic aciduria
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (liver transplantation)
|
2b (4)
|
Standard of care (individual basis)
|
B,C,D,E,F,G (C)
|
|
Aspartylglucosaminuria
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
[62
|
β-Ketothiolase deficiency
|
Avoid fasting, sickday management,
protein restriction
|
5
|
Standard of care
|
C
|
|
Biotin responsive basal ganglia
disease
|
Biotin supplement
|
4
|
Standard of care
|
A,E
|
[66
|
Biotinidase deficiency
|
Biotin supplement
|
2c
|
Standard of care
|
A,E,G
|
[67
|
Cerebral folate receptor-α deficiency
|
Folinic acid
|
4
|
Standard of care
|
A,D,E,F
|
|
Cerebrotendinous xanthomatosis
|
Chenodesoxycholic acid, HMG reductase
inhibitor
|
4
|
Standard of care
|
B,D,E,G
|
|
l.o. Citrullinemia
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Citrullinemia type II
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b (4)
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Co enzyme Q10 deficiency
|
CoQ supplements
|
4
|
Standard of care
|
E,F
|
|
Cobalamin A deficiency
|
Hydroxycobalamin, protein restriction
|
4
|
Standard of care
|
C,G
|
|
Cobalamin B deficiency
|
Hydroxycobalamin, protein restriction
|
4
|
Standard of care
|
C,G
|
|
Cobalamin C deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin D deficiency
|
Hydroxy-/cyanocobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin E deficiency
|
Hydroxy-/methylcobalamin, betaine
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin F deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
C,D,G
|
|
Cobalamin G deficiency
|
Hydroxy-/methylcobalamin, betaine
|
4
|
Standard of care
|
C,D,G
|
|
Congenital intrinsic factor
deficiency
|
Hydroxycobalamin
|
4
|
Standard of care
|
A,E,G
|
[80
|
l.o. CPS deficiency
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
Creatine transporter defect
|
Creatine, glycine, arginine supplements
|
4-5
|
Individual basis
|
F
|
[29
|
DHPR deficiency
|
BH4,diet, amine replacement, folinic
acid
|
4
|
Standard of care
|
A,E
|
[52
|
Ethylmalonic encephalopathy
|
N-acetylcysteine, oral metronidazol
|
4
|
Standard of care
|
E,G
|
[81
|
GAMT deficiency
|
Arginine restriction, creatine &
ornithine supplements
|
4
|
Standard of care
|
B,D,E,F
|
|
Gaucher disease type III
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D,G
|
|
GLUT1 deficiency syndrome
|
Ketogenic diet
|
4
|
Standard of Care
|
F
|
|
l.o. Glutaric acidemia I
|
Lysine restriction, carnitine
supplements
|
2c
|
Standard of care
|
C,D,E,G
|
|
Glutaric acidemia II
|
Carnitine, riboflavin,
β-hydroxybutyrate supplements; sick day management
|
5
|
Standard of care
|
C,G
|
|
GTPCH1 deficiency
|
BH4, amine replacement
|
4
|
Standard of care
|
A,E
|
[91
|
HHH syndrome
|
Dietary protein restriction,
ornithine supplement, sodium benzoate, phenylacetate
|
4
|
Standard of care
|
B,C,D,E,F,G
|
[92
|
HMG-CoA lyase deficiency
|
Protein restriction, avoid fasting,
sick day management,
|
5
|
Standard of care
|
C
|
|
Holocarboxylase synthetase deficiency
|
Biotin supplement
|
4
|
Standard of care
|
A,E,G
|
|
Homocystinuria
|
Methionine restriction, +/−pyridoxine,
+/−betaine
|
2c
|
Standard of care
|
C,D,G
|
|
Hunter syndrome (MPS II)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D,G
|
|
Hurler syndrome (MPS I)
|
Haematopoietic stem cell
transplantation
|
1c
|
Standard of care
|
D,G
|
|
Hyperammonemia–Hyperinsulinism
syndrome
|
Diazoxide
|
4–5
|
Standard of care
|
D
|
|
Imerslund Gräsbeck syndrome
|
Hydroxycobalamin
|
4
|
Standard of Care
|
A,E,G
|
[100
|
l.o. Isovaleric acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
l.o. NAGS deficiency
|
Dietary protein restriction, arginine
supplement, sodium benzoate, phenylbutyrate (Liver transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
l.o. Non-ketotic hyperglycinemia
|
Glycine restriction; +/−sodium
benzoate, NMDA receptor antagonists, other neuromodulating agents
|
4-5
|
Standard of Care
|
B,D,E,F
|
[106
|
Maple syrup urine disease (variant)
|
Dietary restriction branched
amino-acids, avoid fasting, (Liver transplantation)
|
4 & 4
|
Standard of care (Individual basis)
|
B,C,D (A,C)
|
|
MELAS
|
Arginine supplements
|
4–5
|
Standard of Care
|
C,D,E,F
|
[26
|
Menkes disease occipital horn
syndrome
|
Copper histidine
|
4
|
Individual basis
|
D
|
|
l.o. Metachromatic leukodystrophy
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
|
3-Methylcrotonyl glycinuria
|
Dietary protein restriction;
carnitine, glycine, biotin supplements; avoid fasting; sick day management
|
5
|
Standard of care
|
C
|
|
3-Methylglutaconic aciduria type I
|
Carnitine Supplements, Avoid Fasting,
Sick Day Management
|
5
|
Standard of care
|
C
|
[117
|
l.o. Methylmalonic acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
MHBD deficiency
|
Avoid fasting, sick day management,
isoleucine restricted diet
|
5
|
Standard of care
|
C
|
|
mHMG-CoA synthase deficiency
|
Avoid fasting,sick day management,
+/−dietary precursor restriction
|
5
|
Standard of care
|
C
|
|
Molybdenum co-factor deficiency type
A
|
Precursor Z/cPMP
|
4
|
Individual basis
|
A,F
|
[25
|
l.o. MTHFR deficiency
|
Betaine supplements, +/−folate,
carnitine, methionine supplements
|
4
|
Standard of care
|
C,D,G
|
|
Niemann–Pick disease type C
|
Miglustat
|
1b
|
Standard of care
|
D,E
|
|
l.o. OTC deficiency
|
Dietary protein restriction,
citrulline supplements, Sodium benzoate/phenylbutyrate (Liver
transplantation)
|
2b & 4
|
Standard of care (Individual basis)
|
B,C,D,E,F,G (C)
|
|
PCD deficiency
|
BH4
|
4
|
Standard of care
|
A,E
|
[91
|
PDH complex deficiency
|
Ketogenic diet & thiamine
|
4
|
Individual basis
|
D,E,F
|
[122
|
Phenylketonuria
|
Dietary phenylalanine restriction
+/−amino-acid supplements (BH(4) supplement)
|
2a (4)
|
Standard of care (Individual basis)
|
B, D, E (C)
|
|
PHGDH deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
PSAT deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
l.o. Propionic acidemia
|
Dietary protein restriction,
carnitine supplements, avoid fasting, sick day management
|
2c
|
Standard of care
|
C,G
|
|
PSPH deficiency
|
L-serine & +/−glycine supplements
|
4
|
Standard of care
|
D,F
|
|
PTPS deficiency
|
BH4, diet, amine replacement
|
4
|
Standard of care
|
A,E
|
[91
|
Pyridoxine dependent epilepsy
|
Pyridoxine
|
4
|
Standard of care
|
A,F
|
|
Pyrimidine 5-nucleotidase
superactivity
|
Uridine supplements
|
1b
|
Standard of care
|
A,B,F,G
|
[129
|
Sanfilippo syndrome A (MPS IIIa)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
Sanfilippo syndrome B (MPS IIIb)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
Sanfilippo syndrome C (MPS IIIc)
|
Haematopoietic Stemcell Transplantation
|
4–5
|
Individual Basis
|
D
|
|
Sanfilippo syndrome D (MPS IIId)
|
Haematopoietic stem cell
transplantation
|
4–5
|
Individual basis
|
D
|
|
SCOT deficiency
|
Avoid fasting, protein restriction,
sick day management
|
5
|
Standard of care
|
C
|
[65
|
Sjögren–Larsson syndrome
|
Diet: low fat, medium chain &
essential fatty acid supplements & Zileuton
|
5
|
Individual basis
|
D,G
|
|
Sly syndrome (MPS VII)
|
Haematopoietic stem cell
transplantation
|
4-5
|
Individual basis
|
D
|
|
Smith–Lemli–Opitz syndrome
|
Cholesterol & simvastatin
|
4–5
|
Individual basis
|
B,D
|
|
SPR deficiency
|
Amine replacement
|
4
|
Standard of care
|
A,E
|
[134
|
SSADH deficiency
|
Vigabatrin
|
4
|
Individual basis
|
B,F
|
[135
|
Thiamine-responsive encephalopathy
|
Thiamin supplement
|
4-5
|
Standard of care
|
E
|
|
Tyrosine hydroxylase deficiency
|
L-dopa substitution
|
4
|
Standard of care
|
A,E
|
[138
|
Tyrosinemia type II
|
Dietary phenylalanine & tyrosine
restriction
|
4-5
|
Standard of care
|
D,G
|
|
Wilson disease
|
Zinc & tetrathiomolybdate
|
1b
|
Standard of care
|
E,G
|
developmental disorder:
Diagnostic algorithm for identification of treatable causes and new digital resource
Table 2aOverview of the first tier metabolic screening tests denoting
all diseases (with OMIM# and gene(s)) potentially identified per individual
test.
|
|||
Diagnostic test
|
Disease
|
OMIM#
|
Gene
|
Blood tests
|
|||
Plasma amino acids
|
l.o. Argininemia
|
ARG1 (AR)
|
|
Plasma amino acids
|
l.o. Argininosuccinic aciduria
|
ASL (AR)
|
|
Plasma amino acids
|
l.o. Citrullinemia
|
ASS1 (AR)
|
|
Plasma amino acids
|
Citrullinemia type II
|
SLC25A13 (AR)
|
|
Plasma amino acids
|
l.o. CPS deficiency
|
CPS1 (AR)
|
|
Plasma amino acids
|
HHH syndrome (hyperornithinemia,
hyperammonemia, homocitrullinuria)
|
SLC25A15 (AR)
|
|
Plasma amino acids
|
Maple syrup urine disease (variant)
|
BCKDHA/BCKDHB/DBT(AR)
|
|
Plasma amino acids
|
l.o. NAGS deficiency
|
NAGS (AR)
|
|
Plasma amino acids (& UOA incl
orotic acid)
|
l.o. OTC deficiency
|
OTC (X-linked)
|
|
Plasma amino acids
|
Phenylketonuria
|
PAH (AR)
|
|
Plasma amino acids (& UOA)
|
Tyrosinemia type II
|
TAT (AR)
|
|
Plasma amino acids (tHcy)
|
l.o. MTHFR deficiency
|
MTHFR (AR)
|
|
Plasma total homocysteine
|
Cobalamin E deficiency
|
MTRR (AR)
|
|
Plasma total homocysteine
|
Cobalamin G deficiency
|
MTR (AR)
|
|
Plasma total homocysteine (& UOA)
|
Cobalamin F deficiency
|
LMBRD1 (AR)
|
|
Plasma total homocysteine (& OUA)
|
Cobalamin C deficiency
|
MMACHC (AR)
|
|
Plasma total homocysteine (& OUA)
|
Homocystinuria
|
CBS (AR)
|
|
Plasma total homocysteine (& PAA)
|
l.o. MTHFR deficiency
|
MTHFR (AR)
|
|
Plasma total homocysteine (& UOA)
|
Cobalamin D deficiency
|
MMADHC (AR)
|
|
Serum ceruloplasmin & copper
(& serum iron & ferritin)
|
Aceruloplasminemia
|
CP (AR)
|
|
Serum copper & ceruloplasmin
(& urine copper)
|
MEDNIK diseases
|
AP1S1 (AR)
|
|
Serum copper & ceruloplasmin
(urine deoxypyridonoline)
|
Menkes disease/occipital horn
syndrome
|
ATP7A (AR)
|
|
Serum copper & ceruloplasmin
(& urine copper)
|
Wilson disease
|
ATP7B (AR)
|
|
Urine tests
|
|||
Urine creatine metabolites
|
AGAT deficiency
|
GATM (AR)
|
|
Urine creatine metabolites
|
Creatine transporter defect
|
SLC6A8 (X-linked)
|
|
Urine creatine metabolites
|
GAMT deficiency
|
GAMT (AR)
|
|
Urine glycosaminoglycans
|
Hunter syndrome (MPS II)
|
IDS (X-linked)
|
|
Urine glycosaminoglycans
|
Hurler syndrome (MPS I)
|
IDUA (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome A (MPS IIIa)
|
SGSH (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome B (MPS IIIb)
|
NAGLU (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome C (MPS IIIc)
|
HGSNAT (AR)
|
|
Urine glycosaminoglycans
|
Sanfilippo syndrome D (MPS IIId)
|
GNS (AR)
|
|
Urine glycosaminoglycans
|
Sly syndrome (MPS VII)
|
GUSB (AR)
|
|
Urine oligosaccharides
|
α-Mannosidosis
|
MAN2B1 (AR)
|
|
Urine oligosaccharides
|
Aspartylglucosaminuria
|
AGA (AR)
|
|
Urine organic acids
|
β-Ketothiolase deficiency
|
ACAT1 (AR)
|
|
Urine organic acids
|
Cobalamin A deficiency
|
MMAA (AR)
|
|
Urine organic acids
|
Cobalamin B deficiency
|
MMAB (AR)
|
|
Urine organic acids
|
l.o. Glutaric acidemia I
|
GCDH (AR)
|
|
Urine organic acids
|
Glutaric acidemia II
|
ETFA, ETFB, ETFDH(AR)
|
|
Urine organic acids
|
HMG-CoA lyase deficiency
|
HMGCL (AR)
|
|
Urine organic acids
|
Holocarboxylase synthetase deficiency
|
HLCS (AR)
|
|
Urine organic acids
|
3-Methylglutaconic aciduria type I
|
AUH (AR)
|
|
Urine organic acids
|
MHBD deficiency
|
HSD17B10 (X-linked
recessive)
|
|
Urine organic acids
|
mHMG-CoA synthase deficiency
|
HMGCS2 (AR)
|
|
Urine organic acids
|
SCOT deficiency
|
OXCT1 (AR)
|
|
Urine organic acids
|
SSADH deficiency
|
ALDH5A1 (AR)
|
|
Urine organic acids (& ACP)
|
Ethylmalonic encephalopathy
|
ETHE1 (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Isovaleric acidemia
|
IVD (AR)
|
|
Urine organic acids (& ACP)
|
3-Methylcrotonylglycinuria
|
MCC1/MCC2 (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Methylmalonic acidemia
|
MUT (AR)
|
|
Urine organic acids (& tHcy)
|
Cobalamin C deficiency
|
MMACHC (AR)
|
|
Urine organic acids (& tHcy)
|
Cobalamin D deficiency
|
MMADHC (AR)
|
|
Urine organic acids (& tHcy)
|
Homocystinuria
|
CBS (AR)
|
|
Urine organic acids incl orotic acid
(& PAA)
|
l.o. OTC deficiency
|
OTC (X-linked)
|
|
Urine organic acids (& PAA)
|
Tyrosinemia type II
|
TAT (AR)
|
|
Urine organic acids (& ACP)
|
l.o. Propionic acidemia
|
PCCA/PCCB (AR)
|
|
Urine organic acids (tHcy)
|
Cobalamin F deficiency
|
LMBRD1 (AR)
|
|
Urine purines & pyrimidines
|
Lesch–Nyhan syndrome
|
HPRT (AR)
|
|
Urine purines & pyrimidines
|
Molybdenum cofactor deficiency type A
|
MOCS1, MOCS2, (AR)
|
|
Urine purines & pyrimidines
|
Pyrimidine 5-nucleotidase
superactivity
|
NT5C3 (AR)
|
Table 2bOverview of all diseases (in alphabetical order) requiring
second tier biochemical testing, i.e. a specific test per disease approach;
for each disease the OMIM# and gene(s) are listed.
|
|||
Disease
|
OMIM#
|
Gene(s)
|
Diagnostic test
|
(X-linked) Adrenoleukodystrophy
|
ABCD1 (X-linked)
|
Plasma very long chain fatty acids
|
|
Biotin responsive basal ganglia
disease
|
SLC19A3 (AR)
|
Gene analysis
|
|
Biotinidase deficiency
|
BTD (AR)
|
Biotinidase enzyme activity
|
|
Cerebral folate receptor-α deficiency
|
FOLR1 (AR)
|
CSF 5′-methyltetrahydrofolate
|
|
Cerebrotendinous xanthomatosis
|
CYP27A1 (AR)
|
Plasma cholestanol
|
|
Co-enzyme Q10 deficiency
|
COQ2, APTX, PDSS1,PDSS2, CABC1, COQ9(most AR)
|
Co-enzyme Q (fibroblasts) & gene
analysis
|
|
Congenital intrinsic factor
deficiency
|
GIF (AR)
|
Plasma vitamin B12 & folate
|
|
Dihydrofolate reductase deficiency
|
DHFR (AR)
|
CSF 5′-methyltetrahydrofolate
|
|
DHPR deficiency (biopterin
deficiency)
|
QDPR (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Gaucher disease type III
|
GBA (AR)
|
Glucocerebrosidase enzyme activity
(lymphocytes)
|
|
GLUT1 deficiency syndrome
|
SLC2A1 (AR)
|
CSF: plasma glucose ratio
|
|
GTPCH1 deficiency
|
GCH1 (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Hypermanganesemia with dystonia,
polycythemia, and cirrhosis (HMDPC)
|
SLC30A10
|
Whole blood manganese
|
|
Hyperinsulinism hyperammonemia
syndrome
|
GLUD1 (AR)
|
Gene analysis (& ammonia,
glucose, insulin)
|
|
Imerslund Gräsbeck syndrome
|
CUBN & AMN (AR)
|
Plasma vitamin B12 & folate
|
|
MELAS
|
MTTL1, MTTQ, MTTH,MTTK, MTTC, MTTS1,MTND1, MTND5, MTND6,MTTS2 (Mt)
|
Mitochondrial DNA mutation testing
|
|
l.o. Metachromatic leukodystrophy
|
ARSA (AR)
|
Arylsulfatase-α enzyme activity
|
|
Niemann–Pick disease type C
|
NPC1 NPC2 (AR)
|
Filipin staining test (fibroblasts)
& gene analyses
|
|
l.o. Non-ketotic hyperglycinemia
|
AMT/GLDC/GCSH (AR)
|
CSF amino acids (& PAA)
|
|
PCBD deficiency (biopterin deficiency)
|
PCBD1 (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
PDH complex deficiency
|
PDHA1 (X-linked), DLAT(AR), PDHX (AR)
|
Serum & CSF lactate:pyruvate
ratio enzyme activity, gene analysis
|
|
PHGDH deficiency (serine deficiency)
|
PHGDH (AR)
|
CSF amino acids (& PAA)
|
|
PSAT deficiency (serine deficiency)
|
PSAT1 (AR)
|
CSF amino acids (& PAA)
|
|
PSPH deficiency (serine deficiency)
|
PSPH (AR)
|
CSF amino acids (& PAA)
|
|
PTS deficiency (biopterin deficiency)
|
PTS (AR)
|
CSF neurotransmitters & biopterin
loading test
|
|
Pyridoxine dependent epilepsy
|
ALDH7A1 (AR)
|
Urine α-aminoadipic semialdehyde
& plasma pipecolic acid
|
|
Sjögren Larsson syndrome
|
ALDH3A2 (AR)
|
Fatty aldehyde dehydrogenase enzyme
activity
|
|
Smith Lemli Opitz syndrome
|
DHCR7 (AR)
|
Plasma
7-dehydrocholesterol:cholesterol ratio
|
|
SPR deficiency (biopterin deficiency)
|
SPR (AR)
|
CSF neurotransmitters, biopterin
& Phe loading test (enzyme activity, gene analysis)
|
|
Thiamine responsive encephalopathy
|
SLC19A3 (AR)
|
Gene analysis
|
|
Tyrosine hydroxylase deficiency
|
TH (AR)
|
CSF neurotransmitters, gene analysis
|
|
VMAT2 deficiency
|
SLC18A2 (AR)
|
Urine mono-amine metabolites
|